arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

DBV Technologies S.A.

DBVT
$9.83 ▼ -0.15 (-1.55%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
8 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

DBV Technologies S.A. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B
Dividend Yield —
Revenue Growth 35.8% ↗
Op. Margin None
ROIC -87.4% ↗
FCF / Share $-0.87 ↗
Trailing P/E —
Price / Book 8.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.64M
↑ +35.8% —
Net Income Profit after all expenses
$-146.95M
↓ -29.0% —
FCF / Share Free cash flow per share
$-0.87
↑ +20.8% —
Long-Term Debt Long-term obligations
$510.00K
↓ -59.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
10
Cash Quality ↓
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 29 quarters